The FINANCIAL — AstraZeneca will present 33 abstracts from across the respiratory disease portfolio at the 2015 European Respiratory Society (ERS) meeting in Amsterdam, Netherlands, 26-30 September. Data will include results from AstraZeneca’s growing inhaled portfolio of LAMA/LABA therapies, as well as findings from the company’s biologics pipeline and early science programmes.
Maarten Kraan, Vice President, Respiratory, Inflammation and Autoimmune Therapy Area, said: “The data presented at ERS further demonstrate the diversity of AstraZeneca’s portfolio of innovative formulations and devices which provide physicians with the opportunity to select the right therapy to meet their patients’ needs today and in the future.”
Data from growing inhaled respiratory portfolio reinforce importance of delivering combination therapies in a single device
Among key abstracts being presented at ERS are the positive Phase III safety and efficacy data for PT003, the investigational therapy combining glycopyrronium and formoterol fumarate in a pressurised metered dose inhaler (pMDI).
The two pivotal 24 week studies, PINNACLE-1 and PINNACLE-2, investigated the potential of PT003 to improve lung function in patients with Chronic Obstructive Pulmonary Disease (COPD) and showed that the investigational therapy had positive effects on both co-primary and secondary endpoints.1 There were no unexpected safety findings, with adverse events being consistent with previous results from the development programme [#PA4363, Tuesday 29 September, 12:50-14:40 CET]1.
Colin Reisner, Head of Clinical, Respiratory Global Medicines at AstraZeneca, said: “These positive data demonstrate the important role of dual bronchodilators as a treatment for managing COPD. They further support our global regulatory submissions for the first LAMA/LABA combination to be delivered in a pMDI using our unique co-suspension technology.”
Other key data to be presented from the company’s inhaled COPD portfolio includes a study assessing the efficacy and safety of Duaklir Genuair (aclidinium bromide/formoterol fumarate), AstraZeneca’s fixed-dose combination LAMA/LABA therapy. The study assessed morning and night-time symptom prevalence in COPD and the efficacy of aclidinium bromide/formoterol fumarate in symptomatic versus asymptomatic patients [#OA1968, Monday 28 September, 10:45-12:45 CET].
Data highlights from the company’s biologics portfolio show progress in the application of targeted approaches for future respiratory care
Study evaluating the effect of tralokinumab on serum periostin and Immunoglobin E (IgE) levels in uncontrolled severe asthma [#OA1770, Monday 28 September, 08:30-10:30 CET].
Serum periostin has been proposed as a surrogate biomarker for activation of the IL-13 pathway in the lung. The reduction of serum periostin by tralokinumab in subjects with severe uncontrolled asthma further supports this concept.
IgE contributes to the signs and symptoms of asthma and IL-13 induces B cells to produce IgE. The reduction of IgE levels by tralokinumab may help explain its mechanism of action in reducing exacerbations and improving asthma control and asthma-related quality of life that were observed in a subgroup of patients in the Phase IIb trial.
Both findings will be explored further in the ongoing STRATOS Phase III trials.